All Stories

  1. Increased Hydrolysis of Oximino-β-Lactams by CMY-107, a Tyr199Cys Mutant Form of CMY-2 Produced by Escherichia coli

    Article • Antimicrobial Agents and Chemotherapy, October 2015, ASM Journals

    Dr Stathis D. Kotsakis

  2. Characterization of a Mobilizable IncQ Plasmid Encoding Cephalosporinase CMY-4 in Escherichia coli

    Article • Antimicrobial Agents and Chemotherapy, February 2015, ASM Journals

    Dr Stathis D. Kotsakis

  3. OmpK35 and OmpK36 porin variants associated with specific sequence types ofKlebsiella pneumoniae

    Article • Journal of Chemotherapy, August 2013, Taylor & Francis

    Constantinos C Papagiannitsis, Dr Stathis D. Kotsakis

  4. Laboratory evaluation of Brilliance™ CRE Agar for screening carbapenem-resistant Enterobacteriaceae: Performance on a collection of characterised clinical isolates from Greece

    Article • Journal of Global Antimicrobial Resistance, June 2013, Elsevier

    Dr Stathis D. Kotsakis

  5. Characterisation of CTX-M-117, a Pro174Gln variant of CTX-M-15 extended-spectrum β-lactamase, from a bovine Escherichia coli isolate

    Article • International Journal of Antimicrobial Agents, January 2013, Elsevier

    Dr Stathis D. Kotsakis

  6. Effects of the Val211Gly substitution on molecular dynamics of the CMY-2 cephalosporinase: Implications on hydrolysis of expanded-spectrum cephalosporins

    Article • Proteins Structure Function and Bioinformatics, August 2011, Wiley

    Dr Stathis D. Kotsakis

  7. CMY-42, a Novel Plasmid-Mediated CMY-2 Variant AmpC Beta-Lactamase

    Article • Microbial Drug Resistance, June 2011, Mary Ann Liebert Inc

    Dr Stathis D. Kotsakis